Metagenomi, Inc. Common Stock – NASDAQ:MGX
Metagenomi, Inc. Common Stock stock price today
$1.83
-1.91
-51.07%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Metagenomi, Inc. Common Stock stock price monthly change
-27.24%
month
Metagenomi, Inc. Common Stock stock price quarterly change
-27.24%
quarter
Metagenomi, Inc. Common Stock key metrics
Market Cap | 149.32M |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | N/A |
Revenue | N/A |
EBITDA | N/A |
Income | N/A |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeMetagenomi, Inc. Common Stock stock price history
Metagenomi, Inc. Common Stock stock forecast
Metagenomi, Inc. Common Stock financial statements
| 2023 | 44.75M | -68.25M | -152.5% |
|---|
| 2024-05-14 | -0.95 | -1.19 |
|---|
| 2023 | 364842000 | 500.42M | 137.16% |
|---|
| 2022 | 29.72M | -122.2M | 239.59M |
|---|---|---|---|
| 2023 | -91.40M | 45.73M | 1.01M |
Metagenomi, Inc. Common Stock alternative data
| Mar 2024 | 223 |
|---|---|
| Apr 2024 | 236 |
| May 2024 | 236 |
| Jun 2024 | 237 |
| Jul 2024 | 237 |
| Dec 2024 | 236 |
Metagenomi, Inc. Common Stock other data
-
What's the price of Metagenomi, Inc. Common Stock stock today?
One share of Metagenomi, Inc. Common Stock stock can currently be purchased for approximately $1.83.
-
When is Metagenomi, Inc. Common Stock's next earnings date?
Unfortunately, Metagenomi, Inc. Common Stock's (MGX) next earnings date is currently unknown.
-
Does Metagenomi, Inc. Common Stock pay dividends?
No, Metagenomi, Inc. Common Stock does not pay dividends.
-
How much money does Metagenomi, Inc. Common Stock make?
Metagenomi, Inc. Common Stock has a market capitalization of 149.32M. Metagenomi, Inc. Common Stock made a loss 68.26M US dollars in net income (profit) last year or -$1.19 on an earnings per share basis.
-
What is Metagenomi, Inc. Common Stock's stock symbol?
Metagenomi, Inc. Common Stock is traded on the NASDAQ under the ticker symbol "MGX".
-
What is Metagenomi, Inc. Common Stock's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Metagenomi, Inc. Common Stock?
Shares of Metagenomi, Inc. Common Stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Metagenomi, Inc. Common Stock have?
As Dec 2024, Metagenomi, Inc. Common Stock employs 236 workers, which is 0% less then previous month.
-
When Metagenomi, Inc. Common Stock went public?
Metagenomi, Inc. Common Stock is publicly traded company for more then 19 years since IPO on 6 Apr 2006.
-
What is Metagenomi, Inc. Common Stock's official website?
The official website for Metagenomi, Inc. Common Stock is metagenomi.co.
-
How can i contact Metagenomi, Inc. Common Stock?
Metagenomi, Inc. Common Stock can be reached via phone at +51 08714880.
Metagenomi, Inc. Common Stock company profile:
Metagenomi, Inc. Common Stock
metagenomi.coExchange:
NASDAQ
Full time employees:
236
Industry:
Biotechnology
Sector:
Healthcare
Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.
5959 Horton Street
Emeryville, 94608
Emeryville, 94608
:
ISIN: US59102M1045
:
